Ovarian cancer progression is controlled by phenotypic changes in dendritic cells

Journal of Experimental Medicine

Volumn 209, Issue 3, 2012, Pages 495-506

  Scarlett, Uciane K ^a   Rutkowski, Melanie R ^a   Rauwerdink, Adam M ^b   Fields, Jennifer ^b   Escovar Fadul, Ximena ^a   Baird, Jason ^b   Cubillos Ruiz, Juan R ^b   Jacobs, Ana C ^b   Gonzalez, Jorge L ^b   Weaver, John ^b   Fiering, Steven ^b   Conejo Garcia, Jose R ^a  

^a WISTAR INSTITUTE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; OVARY CARCINOMA; PHENOTYPIC VARIATION; PRIORITY JOURNAL; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; BASE SEQUENCE; DENDRITIC CELLS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENES, P53; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; OVARIAN NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MICROENVIRONMENT;

EID: 84858793263     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20111413     Document Type: Article

References (26)

1. Bell, D., A. Berchuck, M. Birrer, J. Chien, D.W. Cramer, F. Dao, R. Dhir, P. Disaia, H. Gabra, P. Glenn, et al; Cancer Genome Atlas Research Network. 2011. Integrated genomic analyses of ovarian carcinoma. Nature. 474:609-615. http://dx.doi.org/10.1038/nature10166
2. Bernardini, M.Q., T. Baba, P.S. Lee, J.C. Barnett, G.P. Sfakianos, A.A. Secord, S.K. Murphy, E. Iversen, J.R. Marks, and A. Berchuck. 2010. Expression signatures of TP53 mutations in serous ovarian cancers. BMC Cancer. 10:237. http://dx.doi.org/10.1186/1471-2407-10-237
3. Clark, C.E., S.R. Hingorani, R. Mick, C. Combs, D.A. Tuveson, and R.H. Vonderheide. 2007. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67:9518-9527. http://dx.doi.org/10.1158/0008-5472.CAN-07-0175
4. Connolly, D.C., R. Bao, A.Y. Nikitin, K.C. Stephens, T.W. Poole, X. Hua, S.S. Harris, B.C. Vanderhyden, and T.C. Hamilton. 2003. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 63:1389-1397
5. Dinulescu, D.M., T.A. Ince, B.J. Quade, S.A. Shafer, D. Crowley, and T. Jacks. 2005. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 11:63-70. http://dx.doi.org/10.1038/nm1173
6. Dunn, G.P., A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber. 2002. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3:991-998. http://dx.doi.org/10.1038/ni1102-991
7. Flesken-Nikitin, A., K.C. Choi, J.P. Eng, E.N. Shmidt, and A.Y. Nikitin. 2003. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 63:3459-3463.
8. Hamanishi, J., M. Mandai, M. Iwasaki, T. Okazaki, Y. Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, et al. 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA. 104:3360-3365. http://dx.doi.org/10.1073/pnas.0611533104
9. Huarte, E., J.R. Cubillos-Ruiz, Y.C. Nesbeth, U.K. Scarlett, D.G. Martinez, R.J. Buckanovich, F. Benencia, R.V. Stan, T. Keler, P. Sarobe, et al. 2008a. Depletion of dendritic cells delays ovarian cancer progressionby boosting antitumor immunity. Cancer Res. 68:7684-7691. http://dx.doi.org/10.1158/0008-5472.CAN-08-1167
10. Huarte, E., J.R. Cubillos-Ruiz, Y.C. Nesbeth, U.K. Scarlett, D.G. Martinez, X.A. Engle, W.F. Rigby, P.A. Pioli, P.M. Guyre, and J.R. Conejo-Garcia. 2008b. PILAR is a novel modulator of human T-cell expansion. Blood. 112:1259-1268. http://dx.doi.org/10.1182/blood-2007-12-130773
11. Jackson, E.L., N. Willis, K. Mercer, R.T. Bronson, D. Crowley, R. Montoya, T. Jacks, and D.A. Tuveson. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:3243-3248. http://dx.doi.org/10.1101/gad.943001
12. Jemal, A., R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun. 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59:225-249. http://dx.doi.org/10.3322/caac.20006
13. Jonkers, J., R. Meuwissen, H. van der Gulden, H. Peterse, M. van der Valk, and A. Berns. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29:418-425. http://dx.doi.org/10.1038/ng747
14. Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K. Ko, F. Zavala, et al. 2002. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 17:211-220. http://dx.doi.org/10.1016/S1074-7613(02)00365-5
15. Koebel, C.M., W. Vermi, J.B. Swann, N. Zerafa, S.J. Rodig, L.J. Old, M.J. Smyth, and R.D. Schreiber. 2007. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450:903-907. http://dx.doi.org/10.1038/nature06309
16. Kurman, R.J., and IeM. Shih. 2011. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 42:918-931. http://dx.doi.org/10.1016/j.humpath.2011.03.003
17. Nagaraj, S., and D.I. Gabrilovich. 2010. Myeloid-derived suppressor cells in human cancer. Cancer J. 16:348-353. http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
18. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D.L. Herber, J. Schneck, and D.I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828-835. http://dx.doi.org/10.1038/nm1609
19. Sato, E., S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A.A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA. 102:18538-18543. http://dx.doi.org/10.1073/pnas.0509182102
20. Scarlett, U.K., J.R. Cubillos-Ruiz, Y.C. Nesbeth, D.G. Martinez, X. Engle, A.T. Gewirtz, C.L. Ahonen, and J.R. Conejo-Garcia. 2009. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancerinfiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 69:7329-7337. http://dx.doi.org/10.1158/0008-5472.CAN-09-0835
21. Schreiber, R.D., L.J. Old, and M.J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 331:1565-1570. http://dx.doi.org/10.1126/science.1203486
22. Wang, Y., R. Wu, K.R. Cho, K.A. Shedden, T.J. Barder, and D.M. Lubman. 2006. Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. Mol. Cell. Proteomics. 5:43-52.
23. Wilke, C.M., I. Kryczek, and W. Zou. 2011. Antigen-presenting cell (APC) subsets in ovarian cancer. Int. Rev. Immunol. 30:120-126. http://dx.doi.org/10.3109/08830185.2011.567362
24. Xing, D., G. Scangas, M. Nitta, L. He, X. Xu, Y.J. Ioffe, P.J. Aspuria, C.Y. Hedvat, M.L. Anderson, E. Oliva, et al. 2009. A role for BRCA1 in uterine leiomyosarcoma. Cancer Res. 69:8231-8235. http://dx.doi.org/10.1158/0008-5472.CAN-09-2543
25. Zammit, D.J., L.S. Cauley, Q.M. Pham, and L. Lefrançois. 2005. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity. 22:561-570. http://dx.doi.org/10.1016/j.immuni.2005.03.005
26. Zhang, L., J.R. Conejo-Garcia, D. Katsaros, P.A. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M.N. Liebman, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348:203-213. http://dx.doi.org/10.1056/NEJMoa020177